Compare MSD & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSD | APYX |
|---|---|---|
| Founded | 1993 | 1982 |
| Country | United States | United States |
| Employees | N/A | 205 |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 169.6M |
| IPO Year | N/A | 1995 |
| Metric | MSD | APYX |
|---|---|---|
| Price | $7.30 | $3.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 69.2K | ★ 217.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | ★ 19.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.93 |
| Revenue Next Year | N/A | $11.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.91 | $1.38 |
| 52 Week High | $7.94 | $4.50 |
| Indicator | MSD | APYX |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 50.84 |
| Support Level | $7.27 | $3.18 |
| Resistance Level | $7.48 | $4.28 |
| Average True Range (ATR) | 0.11 | 0.37 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 28.79 | 61.21 |
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.